新型抗IL-4受体α单抗Dupilumab治疗嗜酸粒细胞增高的中重度持续性哮喘的研究进展

Research progress of dupilumab, a novel monoclonal antibody to the α-subunit of interleukin-4 receptor in treatment of persistent moderate-to-severe asthma with elevated eosinophil levels

支气管哮喘是一种以Th2优势免疫为特征的气道过敏性疾病,其中嗜酸粒细胞性气道炎症、气道高反应性和气道重塑为哮喘三个主要的临床特征。Dupilumab是抗IL-4受体α亚基(IL-4Rα)的单抗,能抑制IL-4Rα与IL-4和IL-13结合并阻断其介导的下游信号转导,从而抑制哮喘气道炎症、气道高反应性和气道重塑的发生发展。本文将就Dupilumab治疗嗜酸粒细胞增高的中重度持续性哮喘的研究进展作一综述。

Bronchial asthma is a Th2 immunity-dominated common airway allergic disease, characterized by eosinophilic airway inflammation, airway hyperresponsiveness and airway remodeling. Dupilumab,a novel monoclonal antibody targeting the α-subunit of IL-4 receptor （IL-4Rα）, is capable of binding with IL-4Rα to block both IL-4 and IL-13-mediated signaling pathways, leading to inhibit the airway inflammation, hyperresponsiveness and remodeling. This paper focused on the progress of Dupilumab in persistent moderate-to-severe asthma with elevated eosinophil levels.